|
Bradford S. Goodwin was elected to the Board of Directors in April 2006. He is Chief Executive Officer of Novacea, Inc., a privately-held biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for cancer. Under his leadership, Novacea has in-licensed three clinical-stage oncology product candidates, including DN-101, which is currently in a pivotal Phase 3 clinical study for the treatment of advanced prostate cancer.
Prior to Novacea, Mr. Goodwin was President, Chief Operating Officer and Founder of Collabra Pharma, a company focused on pharmaceutical product licensing and development. Before starting Collabra, he held various senior executive positions with Genentech, Inc., including Vice President of Finance, and was responsible for treasury, purchasing, risk management, real estate, controllership, tax and long-range planning.
Mr. Goodwin has served on expert advisory committees of the American Institute of Certified Public Accountants and the Financial Accounting Standards Board, and holds a bachelor's degree in business administration from the University of California, Berkeley.
| 